DARWIN EU® - Chondrosarcoma: patient demographics, treatments, and survival in the period 2010-2023

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology

  Drug utilisation
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Medical condition to be studied:
  Chondrosarcoma

Population studied

• Short description of the study population:
  The study population will include all individuals with a first diagnosis of chondrosarcoma identified in each database between 01/01/2010 and 31/12/2023. Participants with a diagnosis of cancer (any, excluding non-melanoma skin cancer) or enchondroma before the diagnosis of chondrosarcoma will be excluded.
• Age groups:
  • Paediatric Population (< 18 years)

    • Preterm newborn infants (0 – 27 days)
    • Term newborn infants (0 – 27 days)
    • Children (2 to < 12 years)
    • Adolescents (12 to < 18 years)
  • Adult and elderly population (≥18 years)

    • Adults (18 to < 65 years)

      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)

      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)

Study design details

• Study design:
  A retrospective cohort study of all newly diagnosed chondrosarcoma cases will be conducted.
• Main study objective:
  To describe demographics, treatments, and overall survival of patients with incident chondrosarcoma, stratified by age, sex, study period, country/database, and, if available, by AJCC/UICC TNM stage categories and histological grade in 2010-2023.; The specific objectives of this study are:; 1. To describe demographic characteristics (age and sex) of patients with chondrosarcoma at the time of diagnosis.; 2. To describe chondrosarcoma treatment with medicines (chemotherapy and biologics) in patients that had undergone or not surgery, radiotherapy, both or neither. ; 3. To estimate the overall survival of newly diagnosed chondrosarcoma patients during the study period (2010-2023).;
• Setting:
  This study will use routinely collected health data from 6 nationwide and region-wide databases in 5 European countries.
• Outcomes:
  Two main outcomes of interest were studied: treatment/s initiated within 0 to 90, 91 to 365, and >365 days after diagnosis and death from any cause. A pre-specified list of chondrosarcoma drug treatments was generated and when possible, patients were classified as having undergone surgery, radiotherapy, none or both. The outcomes were studied in all chondrosarcoma patients and in patients with different AJCC/UICC TNM categories and histological grades, depending on data availability.
• Data analysis plan:
  We described the age and sex of each patient at the time of chondrosarcoma diagnosis, as well as AJCC/UICC TNM categories and histological grades if available with the index date being the date of the diagnosis. ; ; The number and proportion of patients receiving each of a pre-specified list of chondrosarcoma drug treatments was described at index date, 0 to 90, 91 to 365, and >365 days post index date. When possible, this was done separately for patients who had undergone or not surgery, radiotherapy, or both. In addition, results from NCR were stratified by AJCC/UICC TNM categories, chondrosarcoma histological subtypes, tumor site and histological grades. ; ; Overall crude survival (at years 1, 3, 5, and 10) was calculated using data on time at risk of death from any ; cause and the Kaplan-Meier method (KM). For all analyses, numbers and proportions were reported.